Last reviewed · How we verify

NCT05201014: CASCADE

Cancer Survivor Cardiomyopathy Detection

Active, enrolled Last updated 5 September 2025
What this trial tests

trial testing NT-pro-BNP in Cardiovascular Diseases in 112 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
3 March 2022
Primary endpoint
20 September 2026
20 September 2026

Quick facts

Lead sponsorMayo Clinic
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment112
Start date3 March 2022
Primary completion20 September 2026
Estimated completion20 September 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 99, any sex, with Cardiovascular Diseases or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05201014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing